Affiliation:
1. Institute of Pharmacy & Pharmacology, University of South China, Hengyang, Hunan, China
2. Hunan Province Key
Laboratory for Antibody-Based Drug and Intelligent Delivery System, Hunan University of Medicine, Huaihua, China
Abstract
Abstract::
Cisplatin, a primary chemotherapeutic drug, is of great value in the realm of tumor treatment.
However, its clinical efficacy is strictly hindered by issues, such as drug resistance, relapse,
poor prognosis, and toxicity to normal tissue. Cisplatin-based combination therapy has garnered increasing
attention in both preclinical and clinical cancer research for its ability to overcome resistance,
reduce toxicity, and enhance anticancer effects. This review examines three primary co-administration
strategies of cisplatin-based drug combinations and their respective advantages and
disadvantages. Additionally, seven types of combination therapies involving cisplatin are discussed,
focusing on their main therapeutic effects, mechanisms in preclinical research, and clinical
applications. This review also discusses future prospects and challenges, aiming to offer guidance
for the development of optimal cisplatin-based combination therapy regimens for improved cancer
treatment.
Funder
Scientific Research Program of the Health Commission of Hunan Province of China
Hunan Province Key Laboratory for Antibody-based Drug and Intelligent Delivery System Foundation
Publisher
Bentham Science Publishers Ltd.